Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact

References

• Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S, . Incidence and outcome of male breast cancer: An international population-based study. J Clin Oncol2011;29:4381–6.
   PubMed Web of Science ®Google Scholar
• Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjallskog ML. Similarities and differences in the characteristics and primary treatment of breast cancer in men and women – a population based study (Sweden). Acta Oncol2011;50:1083–8.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes – dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736–47.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 2011;378:1812–23.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101: 736–50.
   PubMed Web of Science ®Google Scholar
• Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, . Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study. Breast Cancer Res Treat 2011;126:185–92.
   PubMed Web of Science ®Google Scholar
• Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28: 1684–91.
   PubMed Web of Science ®Google Scholar
• Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, . Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol 2010;73:246–54.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: A population-based study. Cancer 2004;101:51–7.
   PubMed Web of Science ®Google Scholar
• Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, . Male breast carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002;15:853–61.
   PubMed Web of Science ®Google Scholar
• Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, . Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009;11:R28.
   Web of Science ®Google Scholar
• Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, . Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012;25:398–404.
   PubMed Web of Science ®Google Scholar
• Shaaban AM, Ball GR, Brannan RA, Cserni G, Benedetto AD, Dent J, . A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender- specific biological differences. Breast Cancer Res Treat 2012;133:949–58.
   PubMed Web of Science ®Google Scholar
• Johansson I, Nilsson C, Berglund P, Lauss M, Ringner M, Olsson H, . Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 2012;14:R31.
   Web of Science ®Google Scholar
• Johansson I, Nilsson C, Berglund P, Strand C, Jonsson G, Staaf J, . High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 2011;129:747–60.
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, . Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 2008;47:591–9.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, . Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368–76.
   PubMed Web of Science ®Google Scholar
• Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: A multiinstitutional survey. Cancer 1998;83:498–509.
   PubMed Web of Science ®Google Scholar
• Uppsala-Örebro Regional Oncologic Center U, Sweden. Register for breast cancer. 2010.
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.
   PubMed Web of Science ®Google Scholar
• Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001;182:389–92.
   PubMed Web of Science ®Google Scholar
• Rudlowski C, Friedrichs N, Faridi A, Fuzesi L, Moll R, Bastert G, . Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004;84:215–23.
   PubMed Web of Science ®Google Scholar
• Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, . Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 2011;127:601–10.
   PubMed Web of Science ®Google Scholar
• Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, . Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010;28:1813–20.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, . Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418–23.
   PubMed Web of Science ®Google Scholar
• Kanthan R, Fried I, Rueckl T, Senger JL, Kanthan SC. Expression of cell cycle proteins in male breast carcinoma. World J Surg Oncol 2010;8:10.
   PubMed Web of Science ®Google Scholar
• Pich A, Margaria E, Chiusa L. Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol 1994;145:481–9.
   PubMed Web of Science ®Google Scholar